
|Videos|February 28, 2018
Exploring the Role of T-VEC in the Treatment of Metastatic Melanoma
Author(s)Robert Andtbacka, MD
Robert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses a study exploring the role of talimogene laherparapvec (T-VEC; Imlygic) in the treatment of patients with metastatic melanoma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
Dr Tolaney on SG + Pembrolizumab Biomarker Data in First-Line mTNBC
5


































